Results 251 to 260 of about 798,498 (333)

Pediatric spinal ependymomas: Long‐term surgical outcomes in a cohort of 61 cases

open access: yesPediatric Investigation, EarlyView.
Spinal ependymomas are rare in children, with limited long‐term outcome data. In this retrospective study of 61 pediatric patients undergoing surgical resection, gross total resection was achieved in 62.3% and was associated with favorable functional improvement. Recurrence was observed in 31.1% of cases.
Liang Zhang   +3 more
wiley   +1 more source

Opsoclonus‐Myoclonus‐Ataxia Syndrome Associated with Coexisting Anti‐N‐Methyl‐D‐Aspartate Receptor and Glial Fibrillary Acidic Protein Antibodies

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Eriko Igami   +7 more
wiley   +1 more source

Nanoparticle polymeric micellar paclitaxel compared with paclitaxel for advanced esophageal squamous cell carcinoma

open access: yesPrecision Medical Sciences, EarlyView.
The nanoparticle polymeric micellar paclitaxel plus nedaplatin regimen demonstrates superior efficacy and tolerable toxicities compared to the paclitaxel–nedaplatin combination as a first‐line treatment for advanced esophageal squamous cell carcinoma.
Yu‐Qing Cao   +7 more
wiley   +1 more source

One‐year follow‐up after fractionated ultra‐high‐dose‐rate FLASH radiotherapy in patient with extramammary Paget disease of the scrotum

open access: yesPrecision Radiation Oncology, EarlyView.
An elderly male patient with extramammary Paget disease of the scrotum and multiple metastases was treated with fractionated FLASH‐RT (40 Gy in 5 fractions) in the scrotal lesion. Abstract Objective Ultrahigh‐dose‐rate radiotherapy (FLASH‐RT) has been shown to reduce radiation‐induced normal tissue injury in preclinical studies.
Hui Luo   +14 more
wiley   +1 more source

The Rare Upper Thoracic and Cervical Esophageal GIST Resected Through Thoracoscopic Esophageal Mobilization and a Cervical Approach: A Case Report. [PDF]

open access: yesCancer Rep (Hoboken)
Ishii K   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy